At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease.
At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease.
复制标题
DOI：
10.1097/mcp.0000000000000792
复制
发表时间：
2021-09-01
影响因子：
3.3
通讯作者：
Kanthi Y
中科院分区：
文献类型：
--
作者：
Cascino TM;Desai AA;Kanthi Y
2019 年冠状病毒病 (COVID-19) 大流行已导致全球 1.39 亿感染者中近 300 万人死亡。肺血管系统的受累被认为是发病率和死亡率的主要驱动力。我们着手总结有关 COVID-19 引起的肺血管疾病 (PVD) 急性表现的最新知识，并优先考虑可能影响肺动脉高压 (PH) 的长期并发症。急性 COVID-19 感染可导致肺血管系统广泛受累、心肌损伤、持续性肺部疾病和静脉血栓栓塞。 COVID-19 后幸存者经常报告持续症状，并可能面临一系列肺动脉高压的风险，包括第 1 组肺动脉高压、由左心疾病导致的第 2 组肺动脉高压、由肺部疾病和/或缺氧导致的第 3 组肺动脉高压以及第 4 组慢性血栓栓塞性肺动脉高压。 COVID-19 对肺血管系统的影响对于确定疾病严重程度至关重要。虽然目前尚不确定 COVID-19 的长期 PVD 表现，但优化 PH 危险因素的护理和监测 PVD 的发展对于降低长期发病率和改善幸存者的健康至关重要。
The coronavirus disease 2019 (COVID-19) pandemic has led to almost 3,000,000 deaths across 139 million people infected worldwide. Involvement of the pulmonary vasculature is considered a major driving force for morbidity and mortality. We set out to summarize current knowledge on acute manifestations of pulmonary vascular disease (PVD) resulting from COVID-19 and prioritize long-term complications that may impact pulmonary hypertension (PH). Acute COVID-19 infection can result in widespread involvement of the pulmonary vasculature, myocardial injury, evidence of persistent lung disease, and venous thromboembolism. Post COVID-19 survivors frequently report ongoing symptoms and may be at risk for the spectrum of PH, including group 1 pulmonary arterial hypertension, group 2 PH due to left heart disease, group 3 PH due to lung disease and/or hypoxia, and group 4 chronic thromboembolic PH. The impact of COVID-19 on the pulmonary vasculature is central to determining disease severity. While the long-term PVD manifestations of COVID-19 are currently uncertain, optimizing the care of risk factors for PH and monitoring for the development of PVD will be critical to reducing long-term morbidity and improving the health of survivors.
影响因子：
2.6
作者：
Desai AA;Machado RF
通讯作者：
Machado RF